---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic impact of diagnostic testing"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic impact of diagnostic testing. Topics: Genetic testing rates before PARP inhibitor approval: United States oncology records, Biomarker testing rates in metastatic prostate cancer: United States community oncology network, Genomic testing rates and BRCA yield: Dutch registry, Tissue availability for somatic genomic testing, and 6 further topics. 10 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Genetic testing rates before PARP inhibitor approval: United States oncology records

> “Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41).”

Source: [Shore et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33906368/)

<a id="topic-2.2.1.8.4-2"></a>

### Biomarker testing rates in metastatic prostate cancer: United States community oncology network

> “For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10 days (NSCLC), 98 days (prostate), and 23 days (bladder), with differences observed across racial and ethnic groups.”
> “Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively.”

Source: [Mahmud et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13348720/)

<a id="topic-2.2.1.8.4-3"></a>

### Genomic testing rates and BRCA yield: Dutch registry

> “Among 1996 mCRPC patients, genomic analysis (somatic and/or germline) was performed in 23.4% (range 3.8–63.2% across hospitals), identifying BRCAm in 11.3% of patients.”

Source: [Bosch et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13287194/)

<a id="topic-2.2.1.8.4-4"></a>

### Tissue availability for somatic genomic testing

> “A total of 150 pts were enrolled. All had germline and initial ctDNA testing. Results from tissue testing were available in 72 pts.”
> “Sequencing results from tissue were available in only half of pts, highlighting the challenges of obtaining tumor tissue for genomic testing.”

Source: [Shevrin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42161163/)

<a id="topic-2.2.1.8.4-5"></a>

### Genomic test-directed olaparib: United States payer model

> “Olaparib yielded an additional 0.063 and 0.068 of quality-adjusted life year (QALY) with the augmented cost of $7,382 and saved the cost of $ 1,980 compared to standard care in scenario A and B, respectively, which yielded an ICER of $116,903/QALY and a cost-saving option.”
> “Included the NGS cost ($5,800).”

Source: [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)

<a id="topic-2.2.1.8.4-6"></a>

### Germline BRCA testing-guided olaparib: Australian payer model

> “Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU$7,841 and a gain of 0.06 quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) was AU$143,613 per QALY.”

Source: [Teppala et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11570197/)

<a id="topic-2.2.1.8.4-7"></a>

### Germline BRCA testing with cascade testing of relatives: Australian payer model

> “Compared with no testing, BRCA testing in mPCa was associated with an incremental cost of AU$3731 and a gain of 0.014 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio of AU$265 942/QALY. Extending testing to FDRs of variant-positive patients resulted in an incremental cost-effectiveness ratio of AU$16 392/QALY.”

Source: [Teppala et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38977196/)

<a id="topic-2.2.1.8.4-8"></a>

### Cost per PSMA PET scan used in a United States model

| Imaging input | Cost (2021 USD) |
| --- | --- |
| Piflufolastat F 18 PET | “6274.17” |
| Gallium 68 PSMA-11 PET | “6036.17” |
| Fluciclovine F 18 PET | “6336.17” |
| Computed tomography | “241.90” |

Source: [Yee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10811023/)

<a id="topic-2.2.1.8.4-9"></a>

### PSMA PET cost-effectiveness in biochemical recurrence: United States model

> “PSMA-PET had mean increments of $99 000 (95% UI, $55 000-153,000) in costs and 0.58 QALYs (95% UI, 0.35-0.82 QALYs) compared with CTBS, leading to an ICER of $172 000 per QALY, which exceeded the assumed $150 000/QALY willingness-to-pay threshold.”
> “This study found that PSMA-PET may be associated with improved disease detection but may not be cost-effective due to high treatment costs offsetting moderate improvements in QALYs.”

Source: [Kunst et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12552925/)

<a id="topic-2.2.1.8.4-10"></a>

### PSMA PET cost-effectiveness: systematic review

> “A total of seven studies were examined, representing both private and public healthcare systems. Overall, these studies demonstrate high methodological and reporting quality. When compared to existing imaging technologies or standard care practices, PSMA-PET/CT or MRI is cost-effective within country-specific willingness-to-pay thresholds.”

Source: [Sanyal and Rendon (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13033869/)

Additional sources: [de Feria Cardet et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33341285/); [George et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42431822/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
